Description

In this episode, Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshal Mazepa, MD, answer questions from an audience of healthcare professionals on topics related to the management of acquired thrombotic thrombocytopenic purpura (aTTP), including:  

• Rationale of the CAPLAVIE regimen of caplacizumab with corticosteroids and rituximab in aTTP in the acute phase
• Data for caplacizumab in pediatric patients with aTTP
• Initiating rituximab after completion of plasma exchange
• International Society on Thrombosis and Haemostasis guideline recommendations against using aspirin
• Triggers of aTTP episodes aside from infection
• Effect of COVID-19 vaccines and COVID-19 infections on aTTP onset or relapse

Presenters:

Ara Metjian, MD
Associate Professor
Division of Hematology
Department of Medicine
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Paul Coppo, MD, PhD
Professor of Hematology
Hematology Department, AP-HP
Sorbonne University
Paris, France

Marshall Mazepa, MD 
Assistant Professor of Medicine
Division of Hematology, Oncology,  and Transplantation
University of Minnesota
Minneapolis, Minnesota

Link to the complete program, including downloadable slidesets, an expert commentary, an on-demand webcast, and healthcare professional resource guide:
https://bit.ly/3J1fcad

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.